CLINIMIX E 220 MG / 100 ML
HISTIDINE : 220 MG / 100 ML TRYPTOPHAN : 90 MG / 100 ML L-PROLINE : 210 MG / 100 ML L-THREONINE : 210 MG / 100 ML MAGNESIUM CHLORIDE : 24 MG / 100 ML L-ARGININE : 520 MG / 100 ML L-LYSINE HYDROCHLORIDE : 290 MG / 100 ML L-PHENYLALANINE HYDROCHLORIDE : 310 MG / 100 ML SODIUM CHLORIDE : 58.5 MG / 100 ML DEXTROSE : 16.6 G / 100 ML L-VALINE : 230 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-TYROSINE : 20 MG / 100 ML METHIONINE : 290 MG / 100 ML L-ALANINE : 1.04 G / 100 ML GLYCINE : 1.04 G / 100 ML L-ISOLEUCINE : 240 MG / 100 ML L-LEUCINE HYDROCHLORIDE : 310 MG / 100 ML SODIUM ACETATE : 205 MG / 100 ML · DIN 02013967 · BAXTER CORPORATION
Health Canada status: MARKETED
What is CLINIMIX E?
CLINIMIX E 220 MG / 100 ML contains HISTIDINE : 220 MG / 100 ML TRYPTOPHAN : 90 MG / 100 ML L-PROLINE : 210 MG / 100 ML L-THREONINE : 210 MG / 100 ML MAGNESIUM CHLORIDE : 24 MG / 100 ML L-ARGININE : 520 MG / 100 ML L-LYSINE HYDROCHLORIDE : 290 MG / 100 ML L-PHENYLALANINE HYDROCHLORIDE : 310 MG / 100 ML SODIUM CHLORIDE : 58.5 MG / 100 ML DEXTROSE : 16.6 G / 100 ML L-VALINE : 230 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-TYROSINE : 20 MG / 100 ML METHIONINE : 290 MG / 100 ML L-ALANINE : 1.04 G / 100 ML GLYCINE : 1.04 G / 100 ML L-ISOLEUCINE : 240 MG / 100 ML L-LEUCINE HYDROCHLORIDE : 310 MG / 100 ML SODIUM ACETATE : 205 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02013967, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 01-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CLINIMIX E used for?
Source of amino acids and carbohydrate calories when enteral nutrition is insufficient or impossible, to prevent nitrogen loss or negative nitrogen balance.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02013967 |
|---|---|
| Brand name | CLINIMIX E |
| Generic / active ingredient | HISTIDINE : 220 MG / 100 ML TRYPTOPHAN : 90 MG / 100 ML L-PROLINE : 210 MG / 100 ML L-THREONINE : 210 MG / 100 ML MAGNESIUM CHLORIDE : 24 MG / 100 ML L-ARGININE : 520 MG / 100 ML L-LYSINE HYDROCHLORIDE : 290 MG / 100 ML L-PHENYLALANINE HYDROCHLORIDE : 310 MG / 100 ML SODIUM CHLORIDE : 58.5 MG / 100 ML DEXTROSE : 16.6 G / 100 ML L-VALINE : 230 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-TYROSINE : 20 MG / 100 ML METHIONINE : 290 MG / 100 ML L-ALANINE : 1.04 G / 100 ML GLYCINE : 1.04 G / 100 ML L-ISOLEUCINE : 240 MG / 100 ML L-LEUCINE HYDROCHLORIDE : 310 MG / 100 ML SODIUM ACETATE : 205 MG / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 220 MG / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA10 COMBINATIONS |
| AHFS class | 40:20.00 ; 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Nov-2013 |
| Original market date | 1993-12-31 00:00:00 |
How is it administered?
Mix dual chambers before use. Infuse via central vein. Dosage based on individual requirements (approx. 1.0-1.5 g/kg protein for adults). Infusion time 12-24 hours. Use final filter.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Do not freeze. Protect from light after admixture for neonates/children <2 years. Use immediately after opening.
How is it supplied?
Dual-chamber non-PVC bags (1000 mL total admixed volume).
Contraindications
Hypersensitivity; newborns ≤28 days receiving ceftriaxone; pathologically elevated electrolytes; corn allergy; acute renal failure; severe liver failure; congenital amino acid metabolism abnormality.
Warnings and precautions
Risk of pulmonary vascular precipitates. High osmolarity requires central vein administration. Monitor for hyperkalemia, hyperglycemia, and fluid/electrolyte balance. Risk of aluminum toxicity.
What can be used instead?
Other Canadian products sharing ATC code B05BA10 COMBINATIONS. 22 of 79 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINIMIX | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498456 |
| CLINIMIX | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013932 |
| CLINIMIX | 230 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013886 |
| CLINIMIX | 310 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02046709 |
| CLINIMIX | 464 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498464 |
| CLINIMIX | 520 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013940 |
| CLINIMIX | 690 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498448 |
| CLINIMIX E | 261 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498413 |
| CLINIMIX E | 290 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02014076 |
| CLINIMIX E | 58.5 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02142384 |
Who else supplies COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.